

Sychev Dmitry

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4548256/sychev-dmitry-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

175
papers

443
citations

9
h-index

13
g-index

209
ext. papers

554
ext. citations

1
avg, IF

3.85
L-index

#	Paper	IF	Citations
175	Influence of and gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 43-49	2.1	18
174	The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction. <i>Pharmacogenomics and Personalized Medicine</i> , 2016 , 9, 89-95	2.1	16
173	Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. <i>Canadian Journal of Physiology and Pharmacology</i> , 2019 , 97, 781-785	2.4	14
172	Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. <i>Drug Metabolism and Personalized Therapy</i> , 2017 , 32, 129-136	2	14
171	Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. <i>Genetic Testing and Molecular Biomarkers</i> , 2017 , 21, 747-753	1.6	13
170	Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. <i>Human Psychopharmacology</i> , 2018 , 33, e2677	2.3	13
169	Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 113-119	2.1	11
168	polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. <i>Pharmacogenomics and Personalized Medicine</i> , 2017 , 10, 107-114	2.1	9
167	Pharmacogenetics of alcohol addiction: current perspectives. <i>The Application of Clinical Genetics</i> , 2019 , 12, 131-140	3.1	9
166	The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. <i>Pharmacogenomics and Personalized Medicine</i> , 2015 , 8, 111-4	2.1	9
165	Clinical pharmacology in Russia-historical development and current state. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 159-63	2.8	8
164	Comparison of , , , and gene-polymorphism frequency in Russian and Nanai populations. <i>Pharmacogenomics and Personalized Medicine</i> , 2017 , 10, 93-99	2.1	8
163	Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population. <i>Rational Pharmacotherapy in Cardiology</i> , 2019 , 15, 393-406 ^{0.5}	0.5	8
162	ADME pharmacogenetics: future outlook for Russia. <i>Pharmacogenomics</i> , 2019 , 20, 847-865	2.6	8
161	Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. <i>Pharmacogenomics and Personalized Medicine</i> , 2017 , 10, 209-215	2.1	8
160	Decision support systems in clinical practice: The case of venous thromboembolism prevention. <i>International Journal of Risk and Safety in Medicine</i> , 2015 , 27 Suppl 1, S104-5	1.6	8
159	Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. <i>Drug Metabolism and Personalized Therapy</i> , 2018 , 33, 65-73	2	8

158	The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 1-5	2.1	7
157	Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2017 , 10, 253-259	2.1	7
156	Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019 , 26, 413-420	2.9	7
155	EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE. <i>Rational Pharmacotherapy in Cardiology</i> , 2015 , 11, 85-91	0.5	7
154	How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?. <i>Drug Metabolism and Personalized Therapy</i> , 2020 , 35,	2	6
153	Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder. <i>Gene</i> , 2020 , 739, 144513	3.8	6
152	CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. <i>Genetic Testing and Molecular Biomarkers</i> , 2018 , 22, 51-54	1.6	6
151	1846G>A polymorphism of CYP2D6 gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study. <i>Drug Metabolism and Personalized Therapy</i> , 2016 , 31, 205-212	2	6
150	Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). <i>Drug Metabolism and Personalized Therapy</i> , 2018 , 33, 91-98	2	5
149	Potential of the Transdermal Drug Delivery Systems for the Topical Treatment of Chronic Venous Diseases. <i>Flebologiya</i> , 2018 , 12, 40	0.4	5
148	Effects of polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I-II hypertension. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 157-165	2.1	5
147	Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking β blockers in the Republic of Sakha (YAKUTIA). <i>Drug Metabolism and Personalized Therapy</i> , 2018 , 33, 195-200	2	5
146	Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. <i>Drug Metabolism and Personalized Therapy</i> , 2018 , 33, 187-194	2	5
145	An improved extraction protocol for therapeutic dabigatran monitoring using HPLC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019 , 1130-1131, 121808	3.2	4
144	Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers. <i>Pharmacogenomics</i> , 2020 , 21, 677-694	2.6	4
143	May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. <i>Pharmacogenomics and Personalized Medicine</i> , 2020 , 13, 29-37	2.1	4
142	The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. <i>Drug Metabolism and Personalized Therapy</i> , 2018 , 33, 109-118 ²		4
141	APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY. <i>Rational Pharmacotherapy in Cardiology</i> , 2013 , 9, 698-700	0.5	4

140	The effect of anticholinergic medications on cognitive function of patients 80 years and older with essential hypertension. <i>Arterial Hypertension (Russian Federation)</i> , 2019 , 25, 246-257	0.7	4
139	Atrial Fibrillation Associated with Anticancer Drugs. <i>Safety and Risk of Pharmacotherapy</i> , 2020 , 8, 178-190.	0.2	4
138	The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation. <i>Drug Metabolism and Personalized Therapy</i> , 2016 , 31, 173-8	2	4
137	Genotyping and phenotyping CYP3A4/CYP3A5: no association with antiplatelet effect of clopidogrel. <i>Molecular Biology Reports</i> , 2019 , 46, 4195-4199	2.8	3
136	Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. <i>Molecular Biology Reports</i> , 2019 , 46, 2761-2769	2.8	3
135	Effects of polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. <i>Pharmacogenomics</i> , 2020 , 21, 111-123	2.6	3
134	FROM PERSONALIZED TO PRECISION MEDICINE. <i>Rational Pharmacotherapy in Cardiology</i> , 2017 , 13, 69-70.	0.5	3
133	Do and gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?. <i>Pharmacogenomics and Personalized Medicine</i> , 2017 , 10, 243-245	2.1	3
132	CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 107-112	2.1	3
131	A case of hepatic injury suspected to be caused by Canephron N, a Centaurium Hill containing phytotherapeutics. <i>International Journal of Risk and Safety in Medicine</i> , 2011 , 23, 5-6	1.6	3
130	The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2020 , 12, 24-31	0.7	3
129	Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. <i>Drug Metabolism and Personalized Therapy</i> , 2020 ,	2	3
128	Rationality of routine clinical use of olokizumab in COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 68-70	0.4	3
127	FREQUENCY OF CYP2C19 AND ABCB1 GENES POLYMORPHISMS, ASSOCIATED WITH THE CHANGE, CAUSED BY CLOPIDOGREL ANTIAGREGANT AMONG THE RUSSIANS AND THE BURYATS. <i>Siberian Medical Review</i> , 2018 , 43-50	1.5	3
126	Falls in the stationary for patients with cardiovascular diseases of the senior age and polypharmacy. <i>Nervno-Myshechnye Bolezni</i> , 2018 , 8, 19-27	0.2	3
125	Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation. <i>Drug Metabolism and Personalized Therapy</i> , 2020 , 35,	2	3
124	Advanced Age as a Risk Factor of Drug-Induced Diseases. <i>Safety and Risk of Pharmacotherapy</i> , 2021 , 9, 15-24	1.2	3
123	The Development of New Factor Xa Inhibitors Based on Amide Synthesis. <i>Current Drug Discovery Technologies</i> , 2018 , 15, 335-350	1.5	3

122	Evaluation of the Influence of CYP2C9* 2, CYP2C9*3 Gene Polymorphisms on the Efficacy and Safety of Postoperative Analgesia with Ketoprofen in Patients after Cardiac Surgery. <i>Rational Pharmacotherapy in Cardiology</i> , 2021 , 17, 570-575	0.5	3
121	Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients. <i>Drug Metabolism and Personalized Therapy</i> , 2017 , 32, 109-114	2	2
120	Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. <i>Drug Metabolism and Personalized Therapy</i> , 2019 , 34,	2	2
119	PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2017 , 13, 416-421	0.5	2
118	Development of the ontology of patient management technological records for modeling of clinical workflows in a general hospital. <i>Scientific and Technical Information Processing</i> , 2015 , 42, 455-462 ^{0.8}	0.8	2
117	THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE. <i>Rational Pharmacotherapy in Cardiology</i> , 2013 , 9, 404-408	0.5	2
116	Pheno- and genotyping the prescription of drugs metabolized by CYP2D6. <i>Bulletin of Experimental Biology and Medicine</i> , 2002 , 134, 159-60	0.8	2
115	GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA. <i>Russian Journal of Cardiology</i> , 2015 , 92	1.3	2
114	Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 115-119	0.4	2
113	Current and future use of colchicine in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 71-74	0.4	2
112	Drug-induced atrial fibrillation associated with admission of cardiovascular medications. <i>Siberian Medical Review</i> , 2020 , 5-13	1.5	2
111	Risk of postoperative venous thromboembolic complication development in elderly patients. <i>Bulletin of Siberian Medicine</i> , 2018 , 17, 85-93	0.4	2
110	Falls in elderly patients with comorbidity, which were prescribed combined application of psychotropic and cardiovascular medicines. <i>Nervno-Myshechnye Bolezni</i> , 2019 , 9, 67-74	0.2	2
109	Study of the Effect of Polymorphic Markers of the NAT2 Gene on the Risk of Adverse Drug Reactions in Patients with Pulmonary Tuberculosis Who Received Isoniazid and Rifampicin. <i>Safety and Risk of Pharmacotherapy</i> , 2021 , 9, 25-33	1.2	2
108	The effect of and gene polymorphisms on the efficacy and safety of the combination of tramadol and ketorolac used for postoperative pain management in patients after video laparoscopic cholecystectomy. <i>Drug Metabolism and Personalized Therapy</i> , 2021 ,	2	2
107	The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia. <i>Pharmacogenomics and Personalized Medicine</i> , 2016 , 9, 59-63	2.1	2
106	Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects. <i>Pharmacogenomics and Personalized Medicine</i> , 2019 , 12, 329-339	2.1	2
105	Clinically relevant pharmacogenetic markers in Tatars and Balkars. <i>Molecular Biology Reports</i> , 2020 , 47, 3377-3387	2.8	2

104	Physician Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing. <i>Rational Pharmacotherapy in Cardiology</i> , 2018 , 14, 501-508	0.5	2
103	CYP3A subfamily activity affects the equilibrium concentration of Phenazepam in patients with anxiety disorders and comorbid alcohol use disorder. <i>Pharmacogenomics</i> , 2020 , 21, 449-457	2.6	1
102	Importance of the Pharmacokinetics of Valproic Acid in an Individualized Approach to the Treatment of Epileptic Women of Fertile Age. <i>Neuroscience and Behavioral Physiology</i> , 2012 , 42, 963-968	0.3	1
101	Pharmacogenetics of antiviral agents for the treatment of COVID-19. <i>Farmakogenetika i Farmakogenomika</i> , 2022 , 38-41	0.2	1
100	Clinical pharmacology technologies for personalization of cardiovascular diseases drug treatment: focus on direct oral anticoagulants. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019 , 74, 299-306	0.4	1
99	Implementation of clinical decision support system for anticoagulant prescribing for patients with deep vein thrombosis. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2020 , 75, 69-76	0.4	1
98	Current and future use of favipiravir in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 106-114	0.4	1
97	Possibility to use barycytinib in patients with COVID-19, including for treatment of cytokine storm. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 11-14	0.4	1
96	Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 18-22	0.4	1
95	Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 23-27	0.4	1
94	What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 47-49	0.4	1
93	Current and future use of umifenovir in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 75-80	0.4	1
92	Current and future use of dipyridamole in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 92-95	0.4	1
91	Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. <i>Drug Metabolism and Personalized Therapy</i> , 2020 , 35,	2	1
90	MicroRNAs as Novel Biomarkers for P2Y12 - Inhibitors Resistance Prediction. <i>Pharmacogenomics and Personalized Medicine</i> , 2021 , 14, 1575-1582	2.1	1
89	Pharmacogenetic evaluation of adverse events risk in patients with alcohol withdrawal syndrome taking bromdihydrochlorphenylbenzodiazepine: The role of CYP2C19 gene polymorphisms 2017 , 1, 18-26		1
88	Pharmacodynamic gene polymorphism and adverse drug reactionsthen applying antipsychotic drugs 2017 , 1, 5-12		1
87	Stages of development and implementation of personalized medicine technologies in clinical practice 2017 , 1, 1-4		1

86	IMPACT OF CYP3A5, CYP2C9, CYP2C19, AND CYP2D6 POLYMORPHISMS ON PHENAZEPAM SAFETY IN PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2018 , 73, 206-214	0.4	1
85	Influence of CYP3A Activity on the Efficacy and Safety of Fluvoxamine in Patients Depressive Disorders and Comorbid Alcohol Use Disorder. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2018 , 73, 411-419	0.4	1
84	Tapering (deprescribing) of benzodiazepine tranquilizers. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2019 , 11, 89-95	0.7	1
83	Prevalence of polymorphisms in N-acetyltransferase 2 gene among patients of Yakut ethnicity newly diagnosed with pulmonary tuberculosis. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2020 , 75, 154-161	0.4	1
82	Some groups of drugs which use is associated with development of drug-induced atrial fibrillation. <i>Medical Alphabet</i> , 2021 , 1, 20-28	0.3	1
81	Female Gender as a Risk Factor for the Development of Drug-Induced Diseases. <i>Safety and Risk of Pharmacotherapy</i> , 2021 , 9, 85-94	1.2	1
80	THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE. <i>Rational Pharmacotherapy in Cardiology</i> , 2016 , 12, 253-259	0.5	1
79	Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 725-729	3.8	1
78	Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case. <i>Rational Pharmacotherapy in Cardiology</i> , 2018 , 14, 699-702	0.5	1
77	Analysis of the composition of hospitalized patients with the new coronavirus infection COVID-19. <i>Zdravookhranenie Rossiiskoi Federatsii / Ministerstvo Zdravookhraneniia RSFSR</i> , 2021 , 65, 183-190	0.3	1
76	Antibiotic therapy under polypragmatic conditions: a course to safety. <i>Klinicheskaa Mikrobiologia I Antimikrobnaa Himioterapiya</i> , 2021 , 23, 367-373	1.3	1
75	CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis. <i>Terapevticheskii Arkhiv</i> , 2022 , 94, 200-208	0.9	1
74	Structure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2. <i>Sovremennaya Revmatologiya</i> , 2022 , 16, 60-67	0.7	1
73	Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. <i>Drug Metabolism and Personalized Therapy</i> , 2020 , 35,	2	1
72	Drug-induced pulmonary artery hypertension. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2022 , 53-63	0.4	1
71	Pages from the history of therapeutic schools of the Central Institute for Improvement of Doctors [Russian Medical Academy of Continuous Professional Education. <i>Terapevticheskii Arkhiv</i> , 2022 , 94, 596-599	0.9	1
70	Is it possible to use riamilovir to prevent infection and treat COVID-19?. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 15-17	0.4	0
69	Evaluation of the rivaroxaban-influenced effect of ABCB1 and CYP3A5 gene polymorphisms on prothrombin time in patients after total hip or knee replacement surgery. <i>Bulletin of Russian State Medical University</i> , 2018 , 105-109	0.4	0

68	Efficiency and safety of pharmacotherapy for postoperative pain in cardiac surgery. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021 , 20, 2683	0.9	0
67	Olanzapine-Associated Rhabdomyolysis: A Case Report. <i>Cureus</i> , 2021 , 13, e12568	1.2	0
66	Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder. <i>Pharmacogenomics Journal</i> , 2021 , 21, 435-439	3.5	0
65	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring.. <i>Drug Metabolism and Personalized Therapy</i> , 2021 , 37, 41-46	2	0
64	Genetic Risk Factors for Adverse Drug Reactions. <i>Safety and Risk of Pharmacotherapy</i> , 2022 , 10, 48-64	1.2	0
63	CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE. <i>Rational Pharmacotherapy in Cardiology</i> , 2017 , 13, 771-775	0.5	
62	CYP2C8, PTGS-1, 2 gene polymorphisms prevalence associated with sensitivity to non-steroidal anti-inflammatory drugs among North Caucasus ethnic groups. <i>Terapevticheskie Arkhiv</i> , 2021 , 93, 1334-1339	0.9	0
61	Efficiency of treatment of laryngopharyngeal reflux with proton pump inhibitors depending on the CYP2C19 polymorphism. <i>Meditinskiy Sovet</i> , 2022 , 35-43	0.4	
60	Drug-Induced Atrial Fibrillation / Atrial Flutter. <i>Rational Pharmacotherapy in Cardiology</i> , 2022 , 17, 1-18	0.5	
59	The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome. <i>Bulletin of Siberian Medicine</i> , 2020 , 18, 119-126	0.4	
58	The Effect of Polymorphisms in the CYP2D6 and CYP2C9 Genes on the Clinical Efficacy of Tramadol and Ketorolac When Using the Accelerated Recovery Protocol in Patients With Uncomplicated Acute Calculous Cholecystitis Who Underwent Cholecystectomy. <i>Sklifosovsky Journal Emergency Medical Care</i> , 2020 , 9, 391-399	0.5	
57	Rationale for use mefloquine for COVID-19 treatment. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 103-105	0.4	
56	Current and future use of angiotensin II receptor blockers in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 28-31	0.4	
55	Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19?. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 32-34	0.4	
54	Possibilities for the use of tofacitinib in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 35-38	0.4	
53	Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 4-7	0.4	
52	Could canakinumab be used for COVID-19?. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 50-52	0.4	
51	Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 53-59	0.4	

50	Possibilities for the use of anakinra in COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 60-63	0.4
49	Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 64-67	0.4
48	Possibility for the use of bromhexine to prevent infection with SARS-CoV-2. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 8-10	0.4
47	Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 81-86	0.4
46	Current and future use of vitamin D3 in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 87-89	0.4
45	Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 90-91	0.4
44	Dexamethasone use in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 96-98	0.4
43	Current and future use of remdesivir in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 99-102	0.4
42	Anaphylaxis and vitamin D: associations and perspectives. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii</i> , 2020 , 65, 31-36	0.4
41	Influence of the Acetylation Type on the Incidence of Isoniazid-Induced Hepatotoxicity in Patients with Newly Diagnosed Pulmonary Tuberculosis. <i>Antibiotiki I Khimioterapiya</i> , 2020 , 65, 31-36	0.4
40	Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. <i>Psychopharmacology Bulletin</i> , 2021 , 51, 69-80	0.9
39	Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. <i>Psychopharmacology Bulletin</i> , 2021 , 51, 31-42	0.9
38	Importance of using a pharmacogenetic approach to predict individual pharmacokinetics and safety profile of apixaban. <i>Farmakogenetika I Farmakogenomika</i> , 2022 , 4-8	0.2
37	Influence of the NAT2 gene polymorphic markers on the effectiveness and safety of treatment in patients with newly diagnosed pulmonary tuberculosis based on peripheral red blood cell dynamics. <i>Antibiotiki I Khimioterapiya</i> , 2022 , 66, 30-38	0.4
36	Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 39-46	0.4
35	Current methods of optimization of pharmacotherapy in elderly patients in multidisciplinary hospital.. <i>Klinicheskaya Meditsina</i> , 2018 , 95, 1042-1049	0.2
34	Personalisation of antiplatelet therapy and secondary prevention of ischemic stroke.. <i>Klinicheskaya Meditsina</i> , 2018 , 96, 677-687	0.2
33	Association of CYP3A5 (6986A>G) gene polymorphism with the effectiveness of anti-inflammatory therapy in children with bronchial asthma. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii</i> , 2019 , 64, 73-77	0.4

32	The Effect of Cyp2d6 Gene Polymorphism on the Efficacy and Safety of Mirtazapine in Patients with Depressive Disorders Comorbid with Alcohol. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019 , 74, 185-191	0.4
31	MicroRNA and vascular pathology of the eye. <i>Bulletin of Russian State Medical University</i> , 2020 , 5-9	0.4
30	Problems of integrating medical science, image and practical health care: focus on personalized medicine. <i>Farmakogenetika I Farmakogenomika</i> , 2020 , 3-10	0.2
29	Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects. <i>Meditsinskiy Sovet</i> , 2020 , 65-73	0.4
28	Effect of polymorphisms in CYP3A4*22 (rs35599367) C>T, CYP3A5*3 (rs776746) A>G, ABCB1 (rs4148738) C>T and ABCB1 (rs1045642) C>T genes on apixaban anticoagulation: pilot study results. <i>Meditsinskiy Sovet</i> , 2021 , 41-46	0.4
27	Aspects of practical application of STOPP/START criteria in elderly patients with atrial fibrillation and chronic kidney disease in therapeutic department of multi-speciality hospital. <i>Medical Alphabet</i> , 2021 , 57-65	0.3
26	The Continuity of Chronic Medications in Multimorbid Patients during Perioperative Period: Retrospective Analysis. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021 , 76, 210-220	0.4
25	Comparison of Quantitative Analytical Techniques for Dabigatran in Blood Plasma of Humans with Knee Replacements. <i>Pharmaceutical Chemistry Journal</i> , 2019 , 53, 771-774	0.9
24	Vitamin D and chronic spontaneous urticaria: searching for algorithms of personalized therapy. <i>Russian Journal of Allergy</i> , 2020 , 17, 95-101	0.2
23	Polymorphism 3435c> t of the ABCB1 gene (rs1045642) does not affect the mirtazapine efficiency and safety profile in patients with depressive disorders comorbid with alcohol use disorder. <i>Bulletin of Siberian Medicine</i> , 2021 , 19, 73-79	0.4
22	Comparative analysis of N-acetyltransferase 2 genotyping results among patients with newly diagnosed pulmonary tuberculosis residing in the Sakha Republic (Yakutia). <i>Bulletin of Siberian Medicine</i> , 2021 , 19, 102-109	0.4
21	PHARMACOGENETIC STUDIES IN CARDIOLOGY: THE PROBLEM OF "DEPTH" OF THE ISSUE STUDY AND THE CORRECTNESS OF USING "GENETIC" TERMS. <i>Rational Pharmacotherapy in Cardiology</i> , 2018 , 14, 137-139	0.5
20	NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME. <i>Rational Pharmacotherapy in Cardiology</i> , 2018 , 14, 47-52	0.5
19	Analysis of associations between pharmacodynamic genetic factors and antipsychotics effectiveness and safety in adolescents with acute psychotic episodes taking antipsychotics during a 28-day follow-up. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021 , 78-88	0.4
18	Alcohol as a risk factor for drug-induced diseases. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021 , 52-66	0.4
17	Drugs associated with drug-induced interstitial lung diseases. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021 , 39-51	0.4
16	Changes in anticoagulant prescription in a general hospital in 2008-2018. <i>Rational Pharmacotherapy in Cardiology</i> , 2021 , 17, 544-551	0.5
15	Methotrexate Safety in Psoriasis: An Overview. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021 , 76, 254-267	0.4

14	Pharmacogenetic approach to methotrexate-related toxicity prediction in psoriasis. <i>Russian Journal of Skin and Venereal Diseases</i> , 2021 , 24, 119-132	0.1
13	Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder. <i>Psychopharmacology Bulletin</i> , 2021 , 51, 87-104	0.9
12	Antibiotic therapy under polypragmatic conditions: a course to safety. <i>Kliniceskaa Mikrobiologia I Antimikrobnaa Himioterapiq</i> , 2021 , 23, 367-373	1.3
11	Consensus expert opinion on key items in planning and designing clinical trials in geriatric patients. <i>Russian Journal of Geriatric Medicine</i> , 2022 , 398-402	2
10	The effect of and gene polymorphisms on the efficacy and safety of the combination of tramadol and ketorolac used for postoperative pain management in patients after video laparoscopic cholecystectomy.. <i>Drug Metabolism and Personalized Therapy</i> , 2021 , 37, 27-34	2
9	CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes.. <i>Drug Metabolism and Personalized Therapy</i> , 2021 , 37, 47-53	2
8	Meta-analysis of pharmacogenetic decision support systems used in psychiatry. <i>Vestnik Nevrologii, Psihiatrii I Nejrohirurgii</i> , 2021 , 860-869	0.1
7	Drug-induced diarrhea associated with antineoplastic drugs. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2021 , 13, 5-18	0.2
6	Information technologies role in optimizing the application of drugs in clinical practice: a view of a clinical pharmacologist. <i>Ro-Rossiiskij Ūrnal Terapevtičeskoj Praktiki</i> , 2021 , 2, 30-32	0.1
5	Associations of CYP2D6, ABCB1 2677G>T/A and 3435C>T with effectiveness and safety of pharmacotherapy for acute psychotic episodes in adolescents over 28 days. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021 , 39-49	0.4
4	SPEECH AND MENTAL DEVELOPMENT IN CHILDREN WITH CEREBRAL PALSY. <i>Zabajkal'skij Medicinskij Vestnik</i> , 2020 , 18-24	0.1
3	The Impact of Medication Reconciliation on Continuity of Drug Therapy during Perioperative Period. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2022 , 77, 53-61	0.4
2	Drug-induced hypertension. <i>Medical Alphabet</i> , 2022 , 8-13	0.3
1	<CYP2D6> gene polymorphism effect on central hemodynamic parameters in patients with portal hypertension taking propranolol. <i>Meditsinskiy Sovet</i> , 2022 , 83-91	0.4